Monthly Archives: March 2016

Rayno Biopharmaceuticals Update 3/30 – Stuck In A Trading R

Rayno Biopharmaceutical Portfolio Update- Biotechs with Upside Opportunity Caution No Rush to “Load Up” in a Bear Market Since Mid-January all of our previous portfolios were placed on hold and we recommended four new positions as long term holds. Here are initial prices and the current performance: Abbvie (ABBV) Started at $56.49 now at $56.96 Bluebird bio…

Back To Fundamentals & Funding?

With stocks up and treasuries down, there were a couple of interesting contrary trades today in my view. For one, oil prices at the front end of the futures curve did not participate and have been down since the last FOMC non-decision. That may suggest funding and financing, as the overall curve steepened slightly where…

4 Strong Dividend Stocks Surging In 2016

In the words of the chief investment officer of investment advisor firm Richard Bernstein Advisors, “People are paying a lot to get the dividend” and “To think it’s safe is naive.” Intriguing and cautionary at the same time, it again shifts the focus to the ever-enticing concept of dividend investment. In recent times, stock markets…

Deflation Welcome! Lower Third Of Population Goes Deeper In Debt,

A new PEW study on Household Incomes and Expenditures goes a long ways towards explaining why economists who expected a big jump in consumer spending based on falling gasoline prices were dead wrong. The study shows that although expenditures recovered from the downturn, income did not. Also, low-income families spent a far greater share of their income…